Identification of GP100-derived, melanoma-specific cytotoxic T- lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells

Ichiro Kawashtma, Van Tsai, Scott Southwood, Kazutoh Takesako, Esteban Celis, Alessandro Sette

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The human melanocyte lineage-specific antigen gp 100 contains several epitopes recognized by cytotoxic T lymphocytes (CTL). However, most of the epitopes reported to date are HLA-A2.I-restricted. Despite the high frequency of HLAA2.1 in melanoma patients, effective population coverage requires the identification of epitopes restricted by other frequent HLA alleles. Herein, HLA-A3 binding, gp100-derived synthetic peptides were tested for their capacity to elicit anti-melanoma CTL in vitro using CD8+ T cells from healthy donors as responders and peptide-pulsed autologous dendritic cells as antigen-presenting cells. Of 7 peptides tested, 2 (gp100[987] and gp100[1086]) induced CTLs that killed melanoma cell lines expressing HLA- A3 and gp100. Additional MHC-binding studies to various HLA molecules belonging to the HLA-A3 superfamily (HLA-A*II01, -A*3101, -A*3301 and - A*6801) were performed to determine whether these CTL epitopes could further increase potential population coverage. Further experiments indicated that the peptide gp100[987], which bound to HLA-AII with high affinity, was capable of inducing specific CTLs that killed melanoma cells expressing gp100 and HLA-AII molecules. Our results indicate that the gp100[987] peptide corresponds to a CTL epitope which may be restricted by either the HLA-A3 or HLA-AII allele, emphasizing its utility for the design and development of epitope-based therapies for melanoma.

Original languageEnglish (US)
Pages (from-to)518-524
Number of pages7
JournalInternational Journal of Cancer
Volume78
Issue number4
DOIs
StatePublished - Nov 2 1998
Externally publishedYes

Fingerprint

HLA-A3 Antigen
T-Lymphocyte Epitopes
Cytotoxic T-Lymphocytes
Dendritic Cells
Melanoma
Immunization
Epitopes
Peptides
Alleles
HLA-A2 Antigen
HLA-A Antigens
Melanocytes
Antigen-Presenting Cells
Population
In Vitro Techniques
Tissue Donors
T-Lymphocytes
Antigens
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Identification of GP100-derived, melanoma-specific cytotoxic T- lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. / Kawashtma, Ichiro; Tsai, Van; Southwood, Scott; Takesako, Kazutoh; Celis, Esteban; Sette, Alessandro.

In: International Journal of Cancer, Vol. 78, No. 4, 02.11.1998, p. 518-524.

Research output: Contribution to journalArticle

@article{f8d067c24d3c4fff99b9bbe351fc79ef,
title = "Identification of GP100-derived, melanoma-specific cytotoxic T- lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells",
abstract = "The human melanocyte lineage-specific antigen gp 100 contains several epitopes recognized by cytotoxic T lymphocytes (CTL). However, most of the epitopes reported to date are HLA-A2.I-restricted. Despite the high frequency of HLAA2.1 in melanoma patients, effective population coverage requires the identification of epitopes restricted by other frequent HLA alleles. Herein, HLA-A3 binding, gp100-derived synthetic peptides were tested for their capacity to elicit anti-melanoma CTL in vitro using CD8+ T cells from healthy donors as responders and peptide-pulsed autologous dendritic cells as antigen-presenting cells. Of 7 peptides tested, 2 (gp100[987] and gp100[1086]) induced CTLs that killed melanoma cell lines expressing HLA- A3 and gp100. Additional MHC-binding studies to various HLA molecules belonging to the HLA-A3 superfamily (HLA-A*II01, -A*3101, -A*3301 and - A*6801) were performed to determine whether these CTL epitopes could further increase potential population coverage. Further experiments indicated that the peptide gp100[987], which bound to HLA-AII with high affinity, was capable of inducing specific CTLs that killed melanoma cells expressing gp100 and HLA-AII molecules. Our results indicate that the gp100[987] peptide corresponds to a CTL epitope which may be restricted by either the HLA-A3 or HLA-AII allele, emphasizing its utility for the design and development of epitope-based therapies for melanoma.",
author = "Ichiro Kawashtma and Van Tsai and Scott Southwood and Kazutoh Takesako and Esteban Celis and Alessandro Sette",
year = "1998",
month = "11",
day = "2",
doi = "10.1002/(SICI)1097-0215(19981109)78:4<518::AID-IJC20>3.0.CO;2-0",
language = "English (US)",
volume = "78",
pages = "518--524",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Identification of GP100-derived, melanoma-specific cytotoxic T- lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells

AU - Kawashtma, Ichiro

AU - Tsai, Van

AU - Southwood, Scott

AU - Takesako, Kazutoh

AU - Celis, Esteban

AU - Sette, Alessandro

PY - 1998/11/2

Y1 - 1998/11/2

N2 - The human melanocyte lineage-specific antigen gp 100 contains several epitopes recognized by cytotoxic T lymphocytes (CTL). However, most of the epitopes reported to date are HLA-A2.I-restricted. Despite the high frequency of HLAA2.1 in melanoma patients, effective population coverage requires the identification of epitopes restricted by other frequent HLA alleles. Herein, HLA-A3 binding, gp100-derived synthetic peptides were tested for their capacity to elicit anti-melanoma CTL in vitro using CD8+ T cells from healthy donors as responders and peptide-pulsed autologous dendritic cells as antigen-presenting cells. Of 7 peptides tested, 2 (gp100[987] and gp100[1086]) induced CTLs that killed melanoma cell lines expressing HLA- A3 and gp100. Additional MHC-binding studies to various HLA molecules belonging to the HLA-A3 superfamily (HLA-A*II01, -A*3101, -A*3301 and - A*6801) were performed to determine whether these CTL epitopes could further increase potential population coverage. Further experiments indicated that the peptide gp100[987], which bound to HLA-AII with high affinity, was capable of inducing specific CTLs that killed melanoma cells expressing gp100 and HLA-AII molecules. Our results indicate that the gp100[987] peptide corresponds to a CTL epitope which may be restricted by either the HLA-A3 or HLA-AII allele, emphasizing its utility for the design and development of epitope-based therapies for melanoma.

AB - The human melanocyte lineage-specific antigen gp 100 contains several epitopes recognized by cytotoxic T lymphocytes (CTL). However, most of the epitopes reported to date are HLA-A2.I-restricted. Despite the high frequency of HLAA2.1 in melanoma patients, effective population coverage requires the identification of epitopes restricted by other frequent HLA alleles. Herein, HLA-A3 binding, gp100-derived synthetic peptides were tested for their capacity to elicit anti-melanoma CTL in vitro using CD8+ T cells from healthy donors as responders and peptide-pulsed autologous dendritic cells as antigen-presenting cells. Of 7 peptides tested, 2 (gp100[987] and gp100[1086]) induced CTLs that killed melanoma cell lines expressing HLA- A3 and gp100. Additional MHC-binding studies to various HLA molecules belonging to the HLA-A3 superfamily (HLA-A*II01, -A*3101, -A*3301 and - A*6801) were performed to determine whether these CTL epitopes could further increase potential population coverage. Further experiments indicated that the peptide gp100[987], which bound to HLA-AII with high affinity, was capable of inducing specific CTLs that killed melanoma cells expressing gp100 and HLA-AII molecules. Our results indicate that the gp100[987] peptide corresponds to a CTL epitope which may be restricted by either the HLA-A3 or HLA-AII allele, emphasizing its utility for the design and development of epitope-based therapies for melanoma.

UR - http://www.scopus.com/inward/record.url?scp=0031755442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031755442&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19981109)78:4<518::AID-IJC20>3.0.CO;2-0

DO - 10.1002/(SICI)1097-0215(19981109)78:4<518::AID-IJC20>3.0.CO;2-0

M3 - Article

VL - 78

SP - 518

EP - 524

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -